Trial Profile
Effectiveness of Adalimumab biosimilar in Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jun 2020
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 27 Nov 2018 New trial record
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting